The 13,375 restricted stock units are structured to vest over a four-year period, with one-quarter of the total grant maturing annually. This move aligns with NASDAQ Listing Rule 5635(c)(4), which governs the issuance of equity awards as a material condition of employment. Rigel, which focuses on developing therapies for hematologic disorders and cancer, continues to utilize these inducement plans to secure specialized personnel for its research and development pipeline. The grants reflect the company's ongoing strategy to align employee incentives with long-term corporate growth since its founding in 1996.
Rigel Pharmaceuticals Issues Stock Awards to New Hires
South San Francisco-based Rigel Pharmaceuticals has issued restricted stock units to six incoming non-executive employees. The grants, finalized by the company's compensation committee, serve as an inducement for new staff joining the biotechnology firm, adhering to specific NASDAQ regulatory requirements regarding equity compensation for incoming talent.
Comments (0)
No comments yet. Be the first!